ORKA
Oruka Therapeutics, Inc. NASDAQ Listed Aug 8, 1997$89.92
After hrs
$89.00
-1.03%
Mkt Cap $5.4B
52w Low $14.89
74.6% of range
52w High $115.52
50d MA $96.62
200d MA $61.77
P/E (TTM)
—
EV/EBITDA
—
P/B
8.7x
Debt/Equity
0.0x
ROE
-22.3%
P/FCF
-48.8x
RSI (14)
54.60
ATR (14)
$4.70
Beta
-0.61
50d MA
$96.62
200d MA
$61.77
Avg Volume
860.2K
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
221 Crescent Street Building 23, Suite 105 · Menlo Park, MA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | AMC | -0.51 | -0.55 | -7.3% | 105.14 | +2.3% | -0.4% | +2.6% | +0.7% | +2.7% | +1.5% | — |
| May 13, 2026 | AMC | -0.55 | -0.48 | +12.2% | 63.18 | +0.3% | +1.1% | -3.1% | -5.8% | -1.4% | +5.5% | — |
| Mar 12, 2026 | AMC | -0.61 | -0.45 | +26.2% | 31.99 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% | — |
| Nov 12, 2025 | AMC | -0.56 | -0.55 | +1.8% | 28.30 | +5.3% | -6.8% | +2.7% | +4.2% | -2.8% | +3.0% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.46 | +4.2% | 13.05 | +1.3% | +6.9% | +9.9% | -2.2% | +2.5% | -0.8% | — |
| May 14, 2025 | AMC | -0.57 | -0.40 | +29.8% | 9.71 | +8.0% | -2.6% | +6.3% | +2.5% | +3.0% | -0.4% | — |
| Mar 6, 2025 | AMC | -0.68 | -0.49 | +27.9% | 10.07 | -0.9% | +3.9% | +4.6% | +1.1% | +4.4% | -3.5% | — |
| Nov 13, 2024 | AMC | -0.40 | -1.46 | -265.0% | 25.65 | -3.0% | -6.4% | +0.2% | -12.1% | +5.5% | -0.4% | — |
| Aug 27, 2024 | AMC | — | -1.53 | — | 46.56 | -0.8% | -10.1% | -28.4% | -4.0% | -11.5% | +9.8% | — |
| Apr 25, 2024 | AMC | — | -0.14 | — | 41.76 | +5.7% | +2.9% | -4.2% | +1.7% | -6.9% | +0.3% | — |
| Dec 31, 2023 | AMC | — | -0.08 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.10 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.10 | — | 24.36 | -1.0% | +0.5% | -0.5% | +1.0% | +0.5% | -1.0% | — |
| Mar 31, 2023 | AMC | — | -0.09 | — | 23.88 | -0.5% | -2.0% | +2.1% | -2.0% | +1.0% | +2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Barclays | Maintains | Overweight → Overweight | — | $76.39 | $78.21 | +2.4% | -3.1% | -8.0% | +0.5% | -8.5% | +6.2% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $76.39 | $78.21 | +2.4% | -3.1% | -8.0% | +0.5% | -8.5% | +6.2% |
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $69.03 | $90.02 | +30.4% | +10.7% | -3.1% | -8.0% | +0.5% | -8.5% |
| Apr 15 | Wedbush | Maintains | Outperform → Outperform | — | $67.06 | $67.45 | +0.6% | -2.3% | +2.3% | +2.8% | -0.1% | +0.2% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +9.3% | -2.3% | +2.3% | +2.8% |
| Apr 13 | Guggenheim | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +9.3% | -2.3% | +2.3% | +2.8% |
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +9.3% | -2.3% | +2.3% | +2.8% |
| Apr 9 | Guggenheim | Maintains | Buy → Buy | — | $62.01 | $62.60 | +1.0% | +2.6% | -6.3% | +3.0% | +9.3% | -2.3% |
| Apr 7 | Barclays | Maintains | Overweight → Overweight | — | $56.37 | $56.28 | -0.2% | +7.5% | +2.3% | +2.6% | -6.3% | +3.0% |
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $53.31 | $55.00 | +3.2% | +5.7% | +7.5% | +2.3% | +2.6% | -6.3% |
| Apr 6 | UBS | Maintains | Buy → Buy | — | $53.31 | $55.00 | +3.2% | +5.7% | +7.5% | +2.3% | +2.6% | -6.3% |
| Mar 16 | Leerink Partners | Maintains | Outperform → Outperform | — | $40.00 | $41.30 | +3.2% | +4.4% | -1.1% | -1.2% | -4.9% | +0.2% |
| Mar 13 | BTIG | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% |
| Mar 13 | Barclays | Maintains | Overweight → Overweight | — | $31.99 | $32.84 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% |
| Mar 13 | Wedbush | Maintains | Outperform → Outperform | — | $31.99 | $32.84 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% |
| Mar 13 | Stifel | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +4.4% | -1.1% | -1.2% | -4.9% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $30.69 | $31.56 | +2.8% | +2.1% | +2.1% | +1.6% | +2.8% | -0.5% |
| Jan 12 | BTIG | Maintains | Buy → Buy | — | $27.86 | $27.74 | -0.4% | +10.2% | +2.1% | +2.1% | +1.6% | +2.8% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $28.30 | $29.79 | +5.3% | -6.8% | +2.7% | +4.2% | -2.8% | +3.0% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.25 | $27.91 | +2.4% | +1.7% | -0.9% | +0.6% | +1.8% | +0.2% |
| Sep 29 | BTIG | Maintains | Buy → Buy | — | $15.20 | $16.75 | +10.2% | +26.9% | -0.3% | -3.2% | +3.0% | +3.2% |
| Sep 17 | Clear Street | Maintains | Buy → Buy | — | $14.90 | $17.72 | +18.9% | +8.8% | +2.3% | -6.2% | +10.3% | -9.3% |
| Sep 17 | BTIG | Maintains | Buy → Buy | — | $14.90 | $17.72 | +18.9% | +8.8% | +2.3% | -6.2% | +10.3% | -9.3% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.37 | $15.60 | +1.5% | -0.8% | -4.5% | -1.1% | +2.7% | +4.4% |
| Jul 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.06 | $14.13 | +0.5% | +3.4% | -2.1% | +0.1% | -1.7% | -2.0% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $9.71 | $10.49 | +8.0% | -2.6% | +6.3% | +2.5% | +3.0% | -0.4% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.08 | $13.01 | -0.5% | -12.8% | -4.3% | +0.6% | +8.1% | -3.7% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.76 | $20.31 | -2.2% | -2.2% | +3.4% | +0.6% | -5.4% | -4.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.75 | $20.71 | -0.2% | -10.8% | +1.0% | +8.4% | +7.3% | -3.5% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.88 | $28.85 | -0.1% | -3.0% | -2.9% | -0.9% | -1.0% | +3.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Quinlan Paul TOff | General Counsel | Sell | 2,667 | $95.31 | $254K | 29,995 | +1.25% | — |
| Sep 21, 2026 | Quinlan Paul TOff | General Counsel | Sell | 601 | $94.44 | $57K | 32,662 | +1.25% | — |
| Sep 21, 2026 | Quinlan Paul TOff | General Counsel | Sell | 3,832 | $93.32 | $358K | 33,263 | +1.25% | — |
| Sep 21, 2026 | Quinlan Paul TOff | General Counsel | Sell | 2,900 | $92.37 | $268K | 37,095 | +1.25% | — |
| Sep 21, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 533 | $95.75 | $51K | 14,219 | +1.25% | — |
| Sep 15, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 906 | $95.71 | $87K | 235,478 | +1.46% | +1.25% |
| Sep 15, 2026 | Quinlan Paul TOff | General Counsel | Sell | 1,039 | $95.71 | $99K | 29,995 | +1.46% | +1.25% |
| Sep 15, 2026 | Klein Lawrence OttoDir/Off | Chief Executive Officer | Sell | 2,452 | $95.71 | $235K | 923,128 | +1.46% | +1.25% |
| Sep 15, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 560 | $95.71 | $54K | 14,752 | +1.46% | +1.25% |
| Sep 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 947 | $95.71 | $91K | 31,771 | +1.46% | +1.25% |
| Sep 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 100 | $94.22 | $9K | 32,718 | +1.46% | +1.25% |
| Sep 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 1,366 | $92.99 | $127K | 32,818 | +1.46% | +1.25% |
| Sep 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 3,150 | $92.03 | $290K | 34,184 | +1.46% | +1.25% |
| Sep 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 2,384 | $91.10 | $217K | 37,334 | +1.46% | +1.25% |
| Sep 11, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 200 | $94.02 | $19K | 15,312 | +1.46% | +1.25% |
| Sep 11, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 2,208 | $93.26 | $206K | 15,512 | +1.46% | +1.25% |
| Sep 11, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 4,051 | $92.41 | $374K | 17,720 | +1.46% | +1.25% |
| Sep 11, 2026 | Agarwal ArjunOff | Senior Vice President, Finance | Sell | 3,000 | $91.11 | $273K | 21,771 | +1.46% | +1.25% |
| Sep 1, 2026 | Klein Lawrence OttoDir/Off | Chief Executive Officer | Sell | 4,800 | $92.44 | $444K | 925,580 | -0.52% | -2.98% |
| Sep 1, 2026 | Klein Lawrence OttoDir/Off | Chief Executive Officer | Sell | 63,596 | $91.90 | $5.8M | 930,380 | -0.52% | -2.98% |
| Sep 1, 2026 | Klein Lawrence OttoDir/Off | Chief Executive Officer | Sell | 6,604 | $90.79 | $600K | 993,976 | -0.52% | -2.98% |
| Sep 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 4,000 | $92.01 | $368K | 236,384 | -0.52% | -2.98% |
| Sep 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 1,000 | $91.05 | $91K | 240,384 | -0.52% | -2.98% |
| Aug 17, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 2,480 | $112.56 | $279K | 32,718 | +0.37% | -5.13% |
| Aug 17, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 3,320 | $112.01 | $372K | 35,198 | +0.37% | -5.13% |
| Aug 17, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 300 | $110.52 | $33K | 38,518 | +0.37% | -5.13% |
| Aug 17, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 900 | $109.65 | $99K | 38,818 | +0.37% | -5.13% |
| Jul 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 300 | $87.25 | $26K | 32,718 | -4.17% | -1.90% |
| Jul 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 3,803 | $86.68 | $330K | 33,018 | -4.17% | -1.90% |
| Jul 15, 2026 | Goncalves JoanaOff | Chief Medical Officer | Sell | 2,497 | $85.86 | $214K | 36,821 | -4.17% | -1.90% |
8-K · 5.02
!!! Very High
Oruka Therapeutics, Inc. -- 8-K 5.02: Executive Change
Aug 24
8-K · 2.02
!! High
Oruka Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Oruka Therapeutics reported financial results and operational performance, with details available in the furnished press release exhibit for investor review.
Aug 10
8-K · 8.01
!! High
Oruka Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Oruka Therapeutics announced positive Phase 2a EVERLAST-A trial results for ORKA-001 in moderate-to-severe psoriasis, advancing its clinical pipeline and potentially supporting future development plans.
Apr 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 4,990,181 | $475M | New | Jun 2026 |
| 2 | Fmr Llc | 7,431,403 | $365M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,360,971 | $225M | Added | Jun 2026 |
| 4 | Citadel Advisors Llc | 2,238,022 | $213M | Added | Jun 2026 |
| 5 | Deep Track Capital, Lp | 1,926,000 | $183M | New | Jun 2026 |
| 6 | Fairmount Funds Management Llc | 3,705,262 | $182M | — | Mar 2026 |
| 7 | Remedium Capital Partners, Llc | 1,565,661 | $149M | Reduced | Jun 2026 |
| 8 | Viking Global Investors Lp | 1,503,478 | $143M | Reduced | Jun 2026 |
| 9 | Vr Adviser, Llc | 4,148,428 | $126M | — | Dec 2025 |
| 10 | Rtw Investments, Lp | 2,058,148 | $101M | — | Mar 2026 |
| 11 | Aberdeen Group Plc | 646,943 | $62M | Added | Jun 2026 |
| 12 | Pictet Asset Management Holding Sa | 619,076 | $59M | New | Jun 2026 |
| 13 | Vanguard Portfolio Management Llc | 582,409 | $55M | Added | Jun 2026 |
| 14 | Franklin Resources Inc | 1,004,056 | $49M | Added | Mar 2026 |
| 15 | Avidity Partners Management Lp | 760,424 | $37M | New | Mar 2026 |
| 16 | Massachusetts Financial Services Co /ma/ | 364,102 | $35M | New | Jun 2026 |
| 17 | Synergy Asset Management, Llc | 356,301 | $34M | Reduced | Jun 2026 |
| 18 | Jennison Associates Llc | 299,257 | $28M | New | Jun 2026 |
| 19 | Woodline Partners Lp | 574,882 | $28M | — | Mar 2026 |
| 20 | Bellevue Group Ag | 507,008 | $25M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$5.42B
Enterprise Value
$3.98B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.24x
P/B
8.69x
P/S
—
P/FCF
-48.78x
EV/EBITDA
—
Shares Out
45.6M
Financials (TTM)
Revenue
$0
Net Income
-$132.9M
EBITDA
-$141.7M
Free Cash Flow
-$88.4M
Op Cash Flow
-$88.2M
EPS Basic
$-2.31
EPS Diluted
$-2.47
EPS Forward
$-2.28
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$488.6M
Total Liab.
$16.7M
Total Equity
$471.9M
Cash
$337.0M
LT Debt
$0
Book Value/Sh
$10.35
Debt/Equity
0.00x
Current Ratio
22.37
Quick Ratio
22.37
Returns & Growth
ROE
-22.3%
ROA
-21.6%
ROIC
-25.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+53.7%
Price Returns
2W
+0.3%
1M
-12.4%
3M
+13.4%
6M
+127.5%
12M
+507.6%
Technicals
52W High
$115.52
52W Low
$14.89
50d MA
$96.62
200d MA
$61.77
RSI (14)
54.60
ATR (14)
$4.70
Beta
-0.61
Avg Volume
860K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$136.38
High
$200.00
Low
$75.00
Median
$135.50
Data updated apr 26, 2026 5:53pm
· Source: financialmodelingprep.com